Likewise, targeted AML treatments may drive the evolution of a resistant leukemic clone at relapse, thereby affecting MRD testing; e.g., among patients with FLT3-ITD positive AML treated with midostaurin, almost half become FLT3-ITD negative at the time of disease resistance or progression [40], highlighting the dynamic disease nature and need for ongoing adaptive MRD monitoring for AML relapse. Here, FLT3 is linked to acute myeloid leukemia.